Proacta Successfully Raises PLN 2.02 Million in Stock Issue to Boost Development of Innovative Bioinformatics Solutions

Proacta, a bioinformatics company listed on NewConnect, has completed its N series stock issue and raised PLN 2.02 million ($540,000). All available shares offered were allocated to 33 entities. The funds raised will be used for the development and promotion of its own products, in particular the platform ‘Dbam o siebie Smart LAB’.

Proacta is steadily increasing its engagement in the medical sector. The bioinformatics company has introduced its own products, led by the Dbam o siebie Smart LAB platform that launched in July. Due to its dynamic growth and further ambitious plans, the company’s shareholders decided to increase capital by issuing up to 4,049,139 N series shares at a value of PLN 0.50 per share as part of a closed subscription, with pre-emptive rights for existing shareholders. On August 19, 100% of the shares of the new issue that were offered to investors were allocated.

“During the ongoing public offering, we transparently presented our innovative products, further plans and capital needs. The subscription of all shares by investors is not only proof of trust but also confirmation of the right direction of development. The funds raised will cover our key emission goals for development and promotion of our solutions,” informs Arkadiusz Zachwieja, vice president of Proacta S.A.

At the beginning of July, the “Dbam o siebie Smart LAB” platform was launched, classified as a medical device, which supports patients in the analysis of laboratory blood test results. In the initial phase of commercialization, the platform was made available to individual customers (patients). A nationwide informational campaign for the platform is planned for the autumn.

Among Proacta’s products, which the company wants to develop in the next stages, is the “Patient Portal”, used for monitoring health status, managing medical data, and supporting the treatment process. Another proprietary solution is the “Digital Breast Cancer Unit” – an innovative platform that uses advanced technologies to optimize the breast cancer treatment process.

“The past few months have been crucial for the company’s development, proving that our plans to concentrate activities in the healthcare sector are very serious and do not end with one product. Our experience and competencies have been appreciated by investors. I am convinced that our actions in the field of bioinformatics solutions in combination with developing AI technologies will contribute to further expansion and strengthening of the company’s market position,” says Paweł Ciesielka, president of Proacta S.A.

At the turn of July and August, Proacta made significant business and development actions in the healthcare sector. The company established cooperation with Medidesk, including sales support and promotion of products and services aimed at B2B customers. The company’s AI solutions sparked interest among medical institutions, resulting in letters of intent from the World Hearing Center and the University Center for Women’s and Newborn’s Health. In addition, the subsidiary Ve Space signed a three-year contract with the Center for Medical Education worth PLN 1.6 million ($430,000).